Select Publications
Journal articles
2023, 'WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL', Kidney International Reports, 8, pp. S51 - S52, http://dx.doi.org/10.1016/j.ekir.2023.02.118
,2023, 'WCN23-0412 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgA NEPHROPATHY', Kidney International Reports, 8, pp. S271 - S272, http://dx.doi.org/10.1016/j.ekir.2023.02.612
,2023, 'WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY', Kidney International Reports, 8, pp. S350 - S350, http://dx.doi.org/10.1016/j.ekir.2023.02.786
,2022, 'Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply', The New England journal of medicine, 387, pp. 2482 - 2485, http://dx.doi.org/10.1056/NEJMc2208182
,2022, 'Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy', European Heart Journal, 43, pp. 4832 - 4844, http://dx.doi.org/10.1093/eurheartj/ehac444
,2022, 'Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program', Diabetes, Obesity and Metabolism, 24, pp. 2459 - 2464, http://dx.doi.org/10.1111/dom.14832
,2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure', Cardiovascular Diabetology, 21, pp. 194, http://dx.doi.org/10.1186/s12933-022-01619-0
,2022, 'Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice', Heart Lung and Circulation, 31, pp. 1604 - 1611, http://dx.doi.org/10.1016/j.hlc.2022.09.003
,2022, 'Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials', The Lancet, 400, pp. 1788 - 1801, http://dx.doi.org/10.1016/S0140-6736(22)02074-8
,2022, 'Abstract 12404: Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin', Circulation, 146, http://dx.doi.org/10.1161/circ.146.suppl_1.12404
,2022, 'Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria', Journal of the American College of Cardiology, 80, pp. 1721 - 1731, http://dx.doi.org/10.1016/j.jacc.2022.08.772
,2022, 'Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS', Diabetes Care, 45, pp. 2644 - 2652, http://dx.doi.org/10.2337/dc22-0866
,2022, 'Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease', Clinical Pharmacology and Therapeutics, 112, pp. 1098 - 1107, http://dx.doi.org/10.1002/cpt.2721
,2022, 'The ASCEND-ND trial: study design and participant characteristics', Nephrology Dialysis Transplantation, 37, pp. 2157 - 2170, http://dx.doi.org/10.1093/ndt/gfab318
,2022, 'Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.2617
,2022, 'Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.1053
,2022, 'Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial', European Heart Journal, 43, http://dx.doi.org/10.1093/eurheartj/ehac544.2621
,2022, 'Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis', Diabetes, Obesity and Metabolism, 24, pp. 1927 - 1938, http://dx.doi.org/10.1111/dom.14772
,2022, 'Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy - Reply', JAMA, 328, pp. 1108 - 1109, http://dx.doi.org/10.1001/jama.2022.12712
,2022, 'Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis', The Lancet Diabetes and Endocrinology, 10, pp. 645 - 654, http://dx.doi.org/10.1016/S2213-8587(22)00172-3
,2022, 'Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial', Journal of the American Heart Association, 11, pp. e025045, http://dx.doi.org/10.1161/JAHA.121.025045
,2022, 'Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)', Diabetes Care, 45, pp. 1893 - 1899, http://dx.doi.org/10.2337/dc21-2398
,2022, 'Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia', Nephrology Dialysis Transplantation, 37, pp. 1461 - 1471, http://dx.doi.org/10.1093/ndt/gfab237
,2022, 'Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure', JACC: Heart Failure, 10, pp. 498 - 507, http://dx.doi.org/10.1016/j.jchf.2022.03.004
,2022, 'Platform Clinical Trials Within Nephrology—Interpreting the Evidence', American Journal of Kidney Diseases, 80, pp. 143 - 146, http://dx.doi.org/10.1053/j.ajkd.2022.01.430
,2022, 'The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial', Diabetes and Metabolism, 48, pp. 101331, http://dx.doi.org/10.1016/j.diabet.2022.101331
,2022, 'Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 24, pp. 1072 - 1083, http://dx.doi.org/10.1111/dom.14671
,2022, 'Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial', JAMA Internal Medicine, 182, pp. 592 - 602, http://dx.doi.org/10.1001/jamainternmed.2022.0605
,2022, 'Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology', Diabetes, Obesity and Metabolism, 24, pp. 983 - 990, http://dx.doi.org/10.1111/dom.14660
,2022, 'Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial', JAMA - Journal of the American Medical Association, 327, pp. 1888 - 1898, http://dx.doi.org/10.1001/jama.2022.5368
,2022, 'Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized, Controlled Trials', Circulation, 145, pp. 1460 - 1470, http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057736
,2022, 'Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial', Nephrology Dialysis Transplantation, 37, pp. 960 - 972, http://dx.doi.org/10.1093/ndt/gfab065
,2022, 'A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation', Frontiers in Cardiovascular Medicine, 9, http://dx.doi.org/10.3389/fcvm.2022.840611
,2022, 'Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER', Circulation, 145, pp. 575 - 585, http://dx.doi.org/10.1161/CIRCULATIONAHA.121.055459
,2022, 'Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease', Clinical Journal of the American Society of Nephrology, 17, pp. 251 - 259, http://dx.doi.org/10.2215/CJN.08780621
,2022, 'Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial', American Journal of Kidney Diseases, 79, pp. 244 - 256.e1, http://dx.doi.org/10.1053/j.ajkd.2021.05.005
,2022, 'Prevalence of chronic kidney disease in Asia: A systematic review and analysis', BMJ Global Health, 7, pp. e007525, http://dx.doi.org/10.1136/bmjgh-2021-007525
,2022, 'Availability, coverage, and scope of health information systems for kidney care across world countries and regions', Nephrology Dialysis Transplantation, 37, pp. 159 - 167, http://dx.doi.org/10.1093/ndt/gfaa343
,2022, 'Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria', Expert Review of Clinical Pharmacology, 15, pp. 827 - 842, http://dx.doi.org/10.1080/17512433.2022.2108402
,2022, 'Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial', Journal of Diabetes Research, 2022, http://dx.doi.org/10.1155/2022/9998891
,2022, 'A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)', Journal of the American Society of Nephrology, 33, pp. 28 - 28, http://dx.doi.org/10.1681/asn.20223311s128c
,2022, 'A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy', Journal of the American Society of Nephrology, 33, pp. 799 - 799, http://dx.doi.org/10.1681/asn.20223311s1799c
,2022, 'Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials', Hypertension, 79, http://dx.doi.org/10.1161/hyp.79.suppl_1.p201
,2022, 'Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD', Journal of the American Society of Nephrology, 33, pp. 673 - 674, http://dx.doi.org/10.1681/asn.20223311s1673c
,2022, 'Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy', Journal of the American Society of Nephrology, 33, pp. 33 - 34, http://dx.doi.org/10.1681/asn.20223311s133d
,2022, 'Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD', Journal of the American Society of Nephrology, 33, pp. 116 - 116, http://dx.doi.org/10.1681/asn.20223311s1116c
,2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 33, pp. 297 - 298, http://dx.doi.org/10.1681/asn.20223311s1297c
,2022, 'On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D', Journal of the American Society of Nephrology, 33, pp. 631 - 631, http://dx.doi.org/10.1681/asn.20223311s1631d
,2021, 'Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial', European Heart Journal, 42, pp. 4891 - 4901, http://dx.doi.org/10.1093/eurheartj/ehab497
,2021, 'Daprodustat for the treatment of anemia in patients not undergoing dialysis', New England Journal of Medicine, 385, pp. 2313 - 2324, http://dx.doi.org/10.1056/NEJMoa2113380
,